Regeneron Pharmaceuticals, Inc.
Regeneron
REGN · NASDAQ
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $14.3B
- Assets
- $40.6B
- SEC filing
- DEF 14A
- Filed
- April 24, 2026
Executive Compensation
Compensation reported for Regeneron’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Daniel P. Van Plew
Executive Vice President And General Manager, Industrial Operations And Product Supply
$8.8M
Reported total
- Salary
- $983,382
- Stock awards
- $2,699,728
- Incentives
- $965,189
- Option awards
- $4,049,757
- Other
- $82,207
Andrew J. Murphy
Ph.d.executive Vice President, Co-Chief Scientific Officer
$8.5M
Reported total
- Salary
- $819,672
- Stock awards
- $2,699,728
- Incentives
- $815,164
- Option awards
- $4,049,757
- Other
- $92,798
Joseph J. La Rosa
Executive Vice President, General Counsel And Secretary10
$7.5M
Reported total
- Salary
- $916,062
- Stock awards
- $1,799,334
- Incentives
- $1,911,024
- Option awards
- $2,699,810
- Other
- $132,740
Leonard S. Schleifer
M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
$7.3M
Reported total
- Salary
- $1,979,922
- Stock awards
- $0
- Incentives
- $3,682,655
- Option awards
- $0
- Other
- $1,617,972
Christopher Fenimore
Executive Vice President, Finance And Chief Financial Officer
$7M
Reported total
- Salary
- $725,000
- Stock awards
- $2,199,751
- Incentives
- $721,013
- Option awards
- $3,299,977
- Other
- $39,623
George D. Yancopoulos
M.D., Ph.d.board Co-Chair, President And Chief Scientific Officer
$6.9M
Reported total
- Salary
- $1,979,922
- Stock awards
- $0
- Incentives
- $3,682,655
- Option awards
- $0
- Other
- $1,286,892
Leonard S. Schleifer
M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
$7.3M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed April 24, 2026.
- Salary
- $2M
- Incentives
- $3.7M
- Other
- $1.6M
Historical Compensation
Leonard S. Schleifer total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,979,922 | $0 | $7,280,549 |
| 2024 | $1,941,100 | $0 | $6,823,034 |
| 2023 | $1,875,415 | $0 | $8,184,338 |
Named Executive Officers
Leonard S. Schleifer
M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
Regeneron · REGN
$7.3M
FY 2025 · DEF 14A
George D. Yancopoulos
M.D., Ph.d.board Co-Chair, President And Chief Scientific Officer
Regeneron · REGN
$6.9M
FY 2025 · DEF 14A
Christopher Fenimore
Executive Vice President, Finance And Chief Financial Officer
Regeneron · REGN
$7M
FY 2025 · DEF 14A
Daniel P. Van Plew
Executive Vice President And General Manager, Industrial Operations And Product Supply
Regeneron · REGN
$8.8M
FY 2025 · DEF 14A
Andrew J. Murphy
Ph.d.executive Vice President, Co-Chief Scientific Officer
Regeneron · REGN
$8.5M
FY 2025 · DEF 14A
Joseph J. La Rosa
Executive Vice President, General Counsel And Secretary10
Regeneron · REGN
$7.5M
FY 2025 · DEF 14A
Source information
- Company
- Regeneron Pharmaceuticals, Inc.
- Ticker
- REGN · NASDAQ
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- April 24, 2026
- SEC accession number
- 0001308179-26-000340
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company